NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
30.80
+0.40 (1.32%)
Dec 20, 2024, 4:00 PM EST - Market closed
NovoCure Employees
NovoCure had 1,453 employees as of December 31, 2023. The number of employees increased by 133 or 10.08% compared to the previous year.
Employees
1,453
Change (1Y)
133
Growth (1Y)
10.08%
Revenue / Employee
$397,617
Profits / Employee
-$103,086
Market Cap
3.33B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Envista Holdings | 12,800 |
| Perrigo Company | 9,140 |
| Oscar Health | 2,400 |
| Inari Medical | 1,300 |
| Veracyte | 815 |
| Denali Therapeutics | 445 |
| CRISPR Therapeutics AG | 407 |
| Rhythm Pharmaceuticals | 226 |
NVCR News
- 17 days ago - NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha
- 19 days ago - Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields - Seeking Alpha
- 19 days ago - NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients - Benzinga
- 19 days ago - Novocure's pancreatic cancer treatment meets main goal in late-stage study - Reuters
- 19 days ago - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire
- 19 days ago - Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire
- 24 days ago - Novocure to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma - Business Wire